Adenosine A1 antagonists and the cardiorenal syndrome

被引：15

作者：

Gottlieb S.S. ^{[1
]}

机构：

[1] University of Maryland School of Medicine, Baltimore, MD 21201

来源：

Current Heart Failure Reports | 2008年 / 5卷 / 2期

关键词：

Heart Failure; Adenosine; Furosemide; Adenosine Receptor; Ischemic Precondition;

D O I：

10.1007/s11897-008-0017-x

中图分类号：

学科分类号：

摘要：

Adenosine A1 antagonists are being developed for the treatment of renal dysfunction in patients with congestive heart failure. After early small studies prompted hope that these agents could increase urine output without worsening the glomerular filtration rate, larger studies published and presented in 2007 confirmed their beneficial impact on weight and renal function. However, in many studies the renal benefits disappear with higher doses, suggesting that specificity may be lost with higher doses of these drugs. Investigations in animals indicate that there may also be direct benefits on the myocardium and in the lung. Although studies have not shown adverse effects at optimal dosing, the widespread actions of adenosine mandate that safety be established. Ongoing studies should be able to demonstrate whether adenosine A1 antagonists can be used to improve renal function without adversely affecting patients with heart failure. © Springer Science+Business Media, LLC 2008.

引用

页码：105 / 109

页数：4

共 26 条

[1]

Balakrishnan V.S., Coles G.A., Williams J.D., Effects of intravenous adenosine on renal function in healthy human subjects, Am J Physiol, 271, 2 PART 2, (1996)

[2]

Kim S.M., Mizel D., Huang Y.G., Et al., Adenosine as a mediator of macula densa-dependent inhibition of renin secretion, Am J Physiol Renal Physiol, 290, (2006)

[3]

Vallon V., Muhlbauer B., Osswald H., Adenosine and kidney function, Physiol Rev, 86, pp. 901-940, (2006)

[4]

Gellai M., Schreiner G.F., Ruffolo Jr. R.R., Et al., CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic activity, J Pharmacol Exp Ther, 286, pp. 1191-1196, (1998)

[5]

Lucas Jr. D.G., Hendrick J.W., Sample J.A., Et al., Cardiorenal effects of adenosine subtype 1 (A1) receptor inhibition in an experimental model of heart failure, J Am Coll Surg, 194, pp. 603-609, (2002)

[6]

Balakrishnan V.S., Coles G.A., Williams J.D., A potential role for endogenous adenosine in control of human glomerular and tubular function, Am J Physiol, 265, 4 PART 2, (1993)

[7]

Gottlieb S.S., Skettino S.L., Wolff A., Et al., The effects of BG9719 (CVT-124), an A1 adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in congestive heart failure patients, J Am Coll Cardiol, 35, pp. 56-59, (2000)

[8]

Gottlieb S.S., Brater D.C., Thomas I., Et al., BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy, Circulation, 105, pp. 1348-1353, (2002)

[9]

Givertz M.M., Massie B.M., Fields T.K., Et al., The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance, J Am Coll Cardiol, 50, pp. 1551-1560, (2007)

[10]

Dittrich H.C., Gupta D.K., Hack T.C., Et al., The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment, J Card Fail, 13, pp. 609-617, (2007)

← 1 2 3 →